Publication Year

Yoshino T, Hooda N, Younan D, Shitara K, Heinemann V,… Suh M, Reichert H,… Fryzek J, et al. 2023. 127P A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness. Ann Oncol 34(Suppl 4):S1519 [abstract]; DOI:https://doi.org/10.1016/j.annonc.2023.10.262.

View Abstract